RORC antagonist (Boehringer Ingelheim Pharmaceuticals Inc/IDIBAPS)

N/A

Report date: 2025/01/26 16:30:39
NME

Base Information

Drug NameRORC antagonist (Boehringer Ingelheim Pharmaceuticals Inc/IDIBAPS)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear receptor ROR-gamma antagonists
TargetsNuclear receptor ROR-gamma
Therapy Area/IndicationsCrohn Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim Corp
China Registration ClassN/A

Develop Information

Active CompaniesInstitut D'Investigacions Biomediques August Pi I SunyerBoehringer Ingelheim Corp
Inactive CompaniesN/A
Active IndicationsCrohn Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A